Sarepta Therapeutics Inc. (NASDAQ:SRPT) SVP David T. Howton sold 7,000 shares of the stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $420,000.00. Following the transaction, the senior vice president now owns 28,453 shares in the company, valued at $1,707,180. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) opened at 59.10 on Wednesday. The company’s market capitalization is $2.83 billion. Sarepta Therapeutics Inc. has a 12-month low of $8.00 and a 12-month high of $61.60. The company has a 50-day moving average price of $32.78 and a 200 day moving average price of $22.96.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the business earned ($0.87) earnings per share. On average, equities analysts anticipate that Sarepta Therapeutics Inc. will post ($4.17) earnings per share for the current fiscal year.
A number of research analysts have commented on SRPT shares. Oppenheimer Holdings Inc. increased their price target on shares of Sarepta Therapeutics from $60.00 to $76.00 in a research report on Monday, September 19th. Vetr raised Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price objective for the company in a research note on Thursday, June 2nd. WBB Securities reissued a “buy” rating and set a $40.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, June 8th. Robert W. Baird reissued a “buy” rating on shares of Sarepta Therapeutics in a research note on Friday, June 10th. Finally, Needham & Company LLC increased their price objective on Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, July 22nd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Sarepta Therapeutics has an average rating of “Buy” and a consensus target price of $50.01.
Institutional investors have recently modified their holdings of the company. First Midwest Bank Trust Division increased its position in shares of Sarepta Therapeutics by 36.2% in the second quarter. First Midwest Bank Trust Division now owns 32,954 shares of the company’s stock worth $628,000 after buying an additional 8,754 shares in the last quarter. American Century Companies Inc. acquired a new position in shares of Sarepta Therapeutics during the second quarter worth about $651,000. Eagle Asset Management Inc. acquired a new position in shares of Sarepta Therapeutics during the second quarter worth about $6,756,000. Amici Capital LLC acquired a new position in shares of Sarepta Therapeutics during the first quarter worth about $488,000. Finally, LGL Partners LLC increased its position in shares of Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock worth $485,000 after buying an additional 1,000 shares in the last quarter. Institutional investors own 72.09% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.